- +351 213 652 600
- +351 213 632 105
- Send Mail
José M. Marcelino is Assistant Researcher in the Medical Microbiology Unit at the Institute of Hygiene and Tropical Medicine, Universidade NOVA de Lisboa (IHMT/UNL).
He has a biologist degree from the University of Azores and PhD in Biomedical Sciences from University of Lisbon. His main areas of interest are vaccines for HIV and HCV infections and immune humoral response; non- neutralizing and neutralizing antibodies; neutralizations assays; antigenicity and immunogenicity of HIV and HCV envelope glycoproteins; identification of neutralizing epitopes and production of murine and human monoclonal antibodies.
He has participated in several Portuguese projects focused in immune response against HIV and is now the Portuguese Principal Investigator for the European Consortium of HIVERA project, VIHDUAVAX: A combination of two gp41 peptides for a new prophylactic vaccine both neutralizing HIV-1 and inhibiting CD4 depletion.
He is teacher at the Doctoral Program, “Human Genetic and Infectious Diseases” at the IHMT and he is supervisor of postgraduate degrees.
Marcelino, JM is author or co-author of 12 peer-reviewed publications and several oral and poster presentations in international meetings. He was awarded with the several Janssen Virology awards and the Pfizer prize in Clinical Research.
Humoral response in HIV and HCV infection
We are interested in vaccine development; identification, characterization and production of murine and human monoclonal antibodies; neutralization assays using TZM-bl cells; identification of neutralizing viral epitopes; antigenicity and immunogenicity of viral proteins and production of viral particles.
Team: Rute Alexandre Marcelino (PhD Student), Débora Almeida (Master’s Student), Rita Franciosi (Visiting Student)
- Rocha C, Calado R, Borrego P, Marcelino JM, Bártolo I, Rosado L, Cavaco Silva P, Gomes P, Família C, Quintas A, Skar H, Leitner T, Barroso H and Taveira N. Neutralizing antibody response and virus evolution in early HIV-2 infection. Retrovirology. 2013 Oct 24;10 (1):110. IF = 5.660
- Marcelino JM, Borrego P, Nilsson C, Família C, Barroso H, Maltez F, Doroana M, Antunes F, Quintas A and Taveira N. Resistance to antibody neutralization in HIV-2 infection occurs in late stage disease and is associated with X4 tropism. AIDS. 2012 Nov 28;26 (18):2275-2284. IF = 6.407
- Marcelino JM, Borrego P, Barroso H, Quintas A, Novo C and Taveira N. Potent and broadly reactive HIV-2 neutralizing antibodies elicited by a Vaccinia vector-prime C2V3C3-boost vaccination strategy. J Virol. 2010 Dec; 84 (23): 12429-12436. IF = 5.189
- Marcelino JM, Nilsson C, Barroso H, Gomes P, Borrego P, Maltez F, Rosado L, Doroana M, Antunes F, Taveira N. Envelope-specific antibody response in HIV-2 infection: C2V3C3-specific IgG response is associated with disease progression. AIDS. 2008 Nov 12; 22(17): 2257-65. IF = 5.460
- Marcelino JM, Barroso H, Gonçalves F, Silva SM, Novo C, Gomes P, Camacho R, Taveira N. Use of a new dual-antigen enzyme-linked immunosorbent assay to detect and characterize the human antibody response to the human immunodeficiency virus type 2 envelope gp125 and gp36 glycoproteins. J Clin Microbiol. 2006 Feb; 44(2): 607-11. IF = 3.445